Filing Details
- Accession Number:
- 0001209191-20-013037
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-26 16:37:36
- Reporting Period:
- 2020-02-24
- Accepted Time:
- 2020-02-26 16:37:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1446372 | M Paul Silva | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Svp & Controller | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-24 | 864 | $239.23 | 16,012 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2020-02-25 | 283 | $229.66 | 15,729 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 137 | $231.17 | 15,592 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 120 | $232.40 | 15,472 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 150 | $234.50 | 15,322 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 150 | $235.49 | 15,172 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 90 | $236.85 | 15,082 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 150 | $238.40 | 14,932 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 169 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $229.66 (range $229.20 to $230.14).
- Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $231.17 (range $230.73 to $231.47).
- Open market sales reported on this line occurred at a weighted average price of $232.40 (range $232.37 to $232.44).
- Open market sales reported on this line occurred at a weighted average price of $234.50 (range $234.14 to $235.10).
- Open market sales reported on this line occurred at a weighted average price of $235.49 (range $235.15 to $235.87).
- Open market sales reported on this line occurred at a weighted average price of $236.85 (range $236.65 to $237.24).
- Open market sales reported on this line occurred at a weighted average price of $238.40 (range $238.19 to $238.54).
Billionaire Hedge Funds
